We refer to the captioned Scheme of Merger of Kia Health Tech Private Limited (“Transferor Company”), a…
As filed · Updates
What happened
FactWe refer to the captioned Scheme of Merger of Kia Health Tech Private Limited (“Transferor Company”), a. Scheme solely provides for the merger of the Transferor Company with the Company, and does not involve. Tribunal/Regional Director – shall not apply to schemes which solely provide for the merger of a wholly owned.
Why it matters
CapitSignal interpretationA merger fixes a share-exchange ratio, which permanently sets how much of the combined company existing holders own.
What management said before
Prior statements by this company that CapitSignal has recorded changing.
Capex
ContradictedThis operational facility manufactures oral solid and oral liquid formulations and has been USFDA inspected for over a decade with 3 successful inspections.
We expect to commence manufacturing our products at the site in calendar year 2027 after completing implementation of our quality management systems.
Change
FactImplication
CapitSignal interpretationWatch next
Fact- Swap ratio and its valuation basis
- Regulatory and NCLT approvals required
- Appointed date
- We expect to commence manufacturing our products at the site in calendar year 2027 after completing implementa (management committed by FY27)
- So, on the Capex guidance, Ritika, I put it in two parts. One is that for the next couple of year, we are proj (management committed by FY27)
Evidence
- Updates(opens the original filing in a new tab)
- Earlier statement · Q1 FY27
- Latest statement · Q1 FY27
- Earlier statement · Q2 FY25
How CapitSignal classified this
- Reasoning:
- MERGER base 74; matched on subject
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 75%